Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153135 · ClinicalTrials.gov registry record
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,320
- Enrollment target
NCT05153135: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05153135 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,320 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05153135 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,320 participants
- Enrollment target
Study Summary
The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.
Primary Outcome
Healthcare Resource Utilization (HRU) was measured between index date and end of follow-up, and was separately measured during the studied line of therapy, and after the studied line of therapy. Because women have different durations of follow-up, the number of events were reported as the average total number of visits per patient-per-6-months (PPP6M). HRU PPP6M was defined as the total number of visits or services for a patient occurring during the relevant period, reported on a six-month basis
Interventions
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,320 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2020-07-31 |
What the finished NCT05153135 record still lists
NCT05153135 is an observational study that tracks outcomes without assigning an intervention. Its 4,320 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Palbociclib is the first listed.
NCT05153135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05153135 about?
NCT05153135 is a clinical study titled "Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors". The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.
What is the current status of trial NCT05153135?
This trial is currently completed. The enrollment target is 4,320 participants. The study started on 2020-05-08. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT05153135?
The interventions under investigation include: Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT05153135?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI